Jun. 20 at 1:50 PM
$GOSS ....Nice of Leerink to chime in...target..
$6.00.....365% increase if all goes according to plan...nothing guaranteed in biotech as we all know but a 3X or 4X your investment would be nice though...to each our own though ;)! glta
Gossamer Bio (GOSS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on June 16. Analyst Joseph Schwartz from Leerink Partners maintained a Buy rating on the stock and has a
$6.00 price target.
"Joseph Schwartz’s rating is based on several key factors surrounding Gossamer Bio’s recent developments. The completion of enrollment for the Phase 3 PROSERA study, which exceeded initial expectations, indicates strong progress in their clinical trials for seralutinib in treating pulmonary arterial hypertension (PAH). This study is particularly focused on patients with more severe conditions, which aligns with the positive outcomes observed in the earlier Phase 2 TORREY study.
Additionally,..."
https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-gossamer-bio-amid-strong-phase-3-prosera-study-progress-and-competitive-landscape-ratings?mod=mw_quote_news
